Background Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to immune checkpoint blockade, owing to its ...

Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about ...

The trial enrolled 33 patients with severe or very severe forms of AA, most with baseline SALT scores between 50 and 100.

Like other autoimmune diseases, vitiligo can’t be cured, but it can be managed. Learn about the many vitiligo treatments ...

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Tofacitinib Newbury 5 mg and 10 mg film-coated tablets in Sweden as the first country in a Scandinavian re ...

Both stocks are delivering strong returns. Shares of Incyte are up more than 17% this year, while TG Therapeutics is up ...

Teva is planning to progress its anti-IL-15 therapy, TEV-'408 into a Phase IIb trial in vitiligo after the drug demonstrated ...

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...

Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management ...

LONDON & NEW YORK & SAN FRANCISCO, June 30, 2026--(BUSINESS WIRE)--Janus Henderson Group Ltd. ("Janus Henderson", "JHG" or the "Company"), Trian Fund Management, L.P. and its affiliated funds ("Trian" ...

Dr Ray O’Connor takes a look at recent clinical papers on myelofibrosis, including the efficacy of Ruxolitinib based combination therapies in patients with the hematologic malignancy ...